Immix Biopharma (IMMX) vs SpyGlass Pharma (SGP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SpyGlass Pharma is the larger company by market cap ($809.4 million vs $766.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMMX | SGP |
|---|---|---|
| Share price | $9.25 | $24.20 |
| Market cap | $766.85M | $809.44M |
| 1-day change | -2.53% | +1.26% |
| YTD return | +81.45% | — |
| 1-year return | +278.09% | — |
| EPS (TTM) | $-0.88 | $-2.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.10 | $32.44 |
| 52-week low | $2.31 | $17.06 |
| Distance from 52-week high | -38.74% | -25.40% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +162.70% | +81.82% |
| Average volume | 1.65M | 111.13K |
| Shares outstanding | 82.90M | 33.45M |
| Employees | 21 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immix Biopharma
IMMX stock →Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About SpyGlass Pharma
SGP stock →SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions.
Health Care · Medical/Dental Instruments · 76 employees
IMMX vs SGP FAQ
Which is bigger, Immix Biopharma or SpyGlass Pharma?
SpyGlass Pharma (SGP) is larger, with a market capitalization of $809.44M compared with $766.85M for Immix Biopharma (IMMX).
Are Immix Biopharma and SpyGlass Pharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Immix Biopharma and Medical/Dental Instruments for SpyGlass Pharma.